Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | LIPA | P38571 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6130349 | 1.00 | TSHR (0.37) | TSHRNPSR1EPHX1LIPAGLA | |
| SCHEMBL6130372 | 1.00 | TSHR (0.37) | TSHRNPSR1EPHX1LIPAGLA | |
| Bromide SCHEMBL11028367 | 0.97 | TSHR (0.36) | TSHRNPSR1EPHX1LIPAGLA | |
| Bromide SCHEMBL11201644 | 0.97 | TSHR (0.36) | TSHRNPSR1EPHX1LIPAGLA | |
| SCHEMBL2452572 | 0.87 | LIPA (0.33) | TSHRNPSR1EPHX1LIPA | |
| SCHEMBL5615220 | 0.86 | EPHX1 (0.42) | EPHX1LIPAGLAEPHX2HSD11B1 | |
| SCHEMBL5270433 | 0.86 | — | — | |
| SCHEMBL22797 | 0.86 | — | — | |
| SCHEMBL999461 | 0.84 | EPHX1 (0.42) | TSHRNPSR1EPHX1GLAEPHX2 | |
| SCHEMBL16411438 | 0.81 | L3MBTL1 (0.33) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009051337-A1 | PERFLUOROCARBON NANO-EMULSION CONTAINING QUANTUM DOT NANOPARTICLES AND METHOD FOR PREPARING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-04-23 | — | — | WO | claimed |
| US-20050112693-A1 | Diketodiazacyclic compounds, diazacyclic compounds and combinatorial libraries thereof | NEFZI ADEL (US) | 2005-05-26 | — | — | US | claimed |
| US-20030120066-A1 | Synthetic peptides | NEFZI ADEL (US) | 2003-06-26 | — | — | US | claimed |
| EP-1181279-A4 | DIKETODIAZACYCLIC COMPOUNDS, DIAZACYCLIC COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | TORREY PINES INST (US) | 2002-09-25 | — | — | EP | claimed |
| US-6441172-B1 | DI- AND TRI-SUBSTITUTED-1,4-DIAZACYCLIC COMPOUNDS | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES | 2002-08-27 | — | — | US | claimed |
| US-6359144-B1 | BIOSYNTHESIS; SCREENING | LION BIOSCIENCE AG (DE) | 2002-03-19 | — | — | US | claimed |
| EP-1181279-A1 | DIKETODIAZACYCLIC COMPOUNDS, DIAZACYCLIC COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 2002-02-27 | — | — | EP | claimed |
| WO-2000069830-A1 | DIKETODIAZACYCLIC COMPOUNDS, DIAZACYCLIC COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 2000-11-23 | — | — | WO | claimed |
| WO-1998034113-A1 | COMBINATORIAL LIBRARIES OF BICYCLIC GUANIDINE DERIVATIVES AND COMPOUNDS THEREIN | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| US-5786448-A | FOR SCREENING, SYNTHESIZING PEPTIDE DERIVATIVES | TREGA BIOSCIENCES, INC. (US) | 1998-07-28 | — | — | US | claimed |
| WO-1998019693-A1 | COMBINATORIAL LIBRARIES OF CYCLIC UREA AND CYCLIC THIOUREA DERIVATIVES AND COMPOUNDS THEREIN | TREGA BIOSCIENCES, INC. (US) | 1998-05-14 | — | — | WO | claimed |
| EP-0300287-B1 | PROCESS FOR THE REDUCTION OF KETONES | MERCK PATENT GmbH (DE) | 1993-01-07 | — | — | EP | claimed |
| CN-115304606-B | Degradation agent for simultaneously targeting BTK and GSPT proteins | 清华大学 | 2024-04-19 | — | — | CN | disclosed |
| US-20240025849-A1 | INHIBITORS OF NO PRODUCTION | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2024-01-25 | — | — | US | disclosed |
| WO-2024008610-A1 | MACROCYCLIC INHIBITORS OF KRAS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-11 | — | — | WO | disclosed |
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | GALERA LABS, LLC | 2023-07-13 | — | — | US | disclosed |
| US-4307016-A | FUNGICIDES, PROTOZOACIDES OR ANTITUMOR AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1981-12-22 | — | — | US | disclosed |
| US-4294757-A | BLEACHING CELLULOSE FIBERS AND ADDITION OF ALKALI METAL POLYPHOSPHATES AND ALKALI METAL DIETHYLENETRIAMINE PENTA(METHYLENE PHOSPHONAT) | TAKEDA CHEMICAL INDUSTRIES, LTD (JP) | 1981-10-13 | — | — | US | disclosed |
| EP-0014402-A1 | Novel 20-0-acylmaytansinoids, process for their preparation and pharmaceutical compositions containing them | Takeda Chemical Industries, Ltd. (JP) | 1980-08-20 | — | — | EP | disclosed |
| EP-0004466-A1 | Demethyl maytansinoids and methods for producing them | Takeda Chemical Industries, Ltd. (JP) | 1979-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | TSHR 4467/4885NPSR1 3198/4885EPHX1 3572/4885 |
| US-20240025849-A1 | INHIBITORS OF NO PRODUCTION | NOS2, NOS1, NOS3 | TSHR 2975/4885NPSR1 1256/4885EPHX1 881/4885 |
| US-20050112693-A1 | Diketodiazacyclic compounds, diazacyclic compounds and combinatorial libraries thereof | DHPS, DCK, DAZAP1 | TSHR 4153/4885NPSR1 4189/4885EPHX1 1807/4885 |
| US-20030120066-A1 | Synthetic peptides | VIP, NGLY1, GRPR | TSHR 1043/4885NPSR1 814/4885EPHX1 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.